Meta-Analysis of Intensive Lipid-Lowering Therapy in Patients With Polyvascular Disease.
lipid‐lowering
low‐density lipoprotein cholesterol
polyvascular
Journal
Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
pubmed:
16
2
2021
medline:
21
10
2021
entrez:
15
2
2021
Statut:
ppublish
Résumé
Background Polyvascular atherosclerotic disease is associated with an increased risk of future cardiovascular events. Intensive lipid-lowering therapy (ILT) may mitigate this risk. The aims of this study-level meta-analysis were to examine the effects of ILT in patients with polyvascular disease and whether baseline low-density lipoprotein cholesterol (LDL-C) may determine the level of benefit. Methods and Results Electronic databases were searched through January 2020 to identify randomized controlled trials of treatments targeting upregulation of LDL-C receptors (ie, statins, ezetimibe, and PCSK9 [proprotein convertase subtilisin-kexin type 9] inhibitors). The primary end point was major adverse vascular events as defined by the included studies. A total of 94 362 patients (14 821 [18.6%] with polyvascular disease) from 7 studies were included. In patients with monovascular disease, ILT was associated with a 13% reduction in the primary end point (rate ratio [RR] 0.87; 95% CI, 0.81-0.93 [
Identifiants
pubmed: 33586467
doi: 10.1161/JAHA.120.017948
pmc: PMC8174253
doi:
Substances chimiques
Biomarkers
0
Hypolipidemic Agents
0
Lipids
0
Types de publication
Journal Article
Meta-Analysis
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e017948Références
N Engl J Med. 2011 Dec 1;365(22):2078-87
pubmed: 22085316
Atherosclerosis. 2018 Dec;279:100-106
pubmed: 30227984
JACC Cardiovasc Interv. 2010 Mar;3(3):332-9
pubmed: 20298994
Radiology. 2014 May;271(2):381-9
pubmed: 24592924
Curr Drug Metab. 2019;20(1):72-82
pubmed: 30112987
PLoS One. 2017 Jul 26;12(7):e0181668
pubmed: 28746385
Circ Cardiovasc Interv. 2019 Dec;12(12):e007385
pubmed: 31833412
Atherosclerosis. 2011 Dec;219(2):743-9
pubmed: 21899843
J Am Coll Cardiol. 2019 Sep 3;74(9):1167-1176
pubmed: 30898609
JAMA. 2006 Jan 11;295(2):180-9
pubmed: 16403930
Atherosclerosis. 2020 Jan;293:75-78
pubmed: 31865057
Atherosclerosis. 2014 Apr;233(2):707-712
pubmed: 24603217
JAMA. 2018 Apr 3;319(13):1331-1340
pubmed: 29525821
JAMA. 2018 Apr 17;319(15):1566-1579
pubmed: 29677301
Heart. 2015 Mar;101(5):356-62
pubmed: 25595417
Stroke. 2017 Nov;48(11):3057-3063
pubmed: 29030478
PLoS One. 2013 Oct 01;8(10):e76298
pubmed: 24098467
Circulation. 2018 Jan 23;137(4):338-350
pubmed: 29133605
Lancet. 2019 Nov 2;394(10209):1629-1637
pubmed: 31570255
Lancet Diabetes Endocrinol. 2018 Dec;6(12):934-943
pubmed: 30396865
Eur Heart J. 2009 May;30(10):1195-202
pubmed: 19339264
JAMA. 2016 Dec 13;316(22):2373-2384
pubmed: 27846344
Circulation. 2019 Mar 19;139(12):1483-1492
pubmed: 30586750
J Am Coll Cardiol. 2020 Jan 21;75(2):240-241
pubmed: 31948655
Lancet. 2010 Nov 13;376(9753):1658-69
pubmed: 21067805
J Am Heart Assoc. 2021 Feb;10(5):e017948
pubmed: 33586467
Lancet. 2016 Nov 19;388(10059):2532-2561
pubmed: 27616593
Lancet. 2002 Jul 6;360(9326):7-22
pubmed: 12114036
Int J Cardiol. 2013 Oct 9;168(4):3715-20
pubmed: 23849964
Int J Clin Pract. 2009 Apr;63(4):547-59
pubmed: 19222610
Eur Heart J Cardiovasc Pharmacother. 2017 Jan;3(1):58-67
pubmed: 27816944
Eur Heart J. 2018 Apr 7;39(14):1131-1143
pubmed: 29045644
J Am Coll Cardiol. 2013 Jul 2;62(1):21-9
pubmed: 23644090
N Engl J Med. 1995 Nov 16;333(20):1301-7
pubmed: 7566020
Oncotarget. 2017 Jun 20;8(25):41582-41589
pubmed: 28177908
Eur Heart J. 2020 Jan 1;41(1):111-188
pubmed: 31504418
Curr Probl Cardiol. 2021 Mar;46(3):100432
pubmed: 31285037
J Clin Epidemiol. 2009 Oct;62(10):1006-12
pubmed: 19631508
JACC Cardiovasc Imaging. 2017 Mar;10(3):241-249
pubmed: 28279371